|
市場調查報告書
體外檢驗藥：治療領域動向
In Vitro Diagnostics Deals: Therapeutic Area Trends
|
本報告已在2011年12月21日停止出版。
體外檢驗在醫療上是不可或缺的，一般相信約有6~7成的醫療決策與檢驗的結果有關。
廣泛調查醫療業界的美國專業市調公司 Decision Resources Inc. （總公司：麻州），調查與分析使用體外檢驗藥的治療領域動向，並有系統地出版綜合報告書 "In Vitro Diagnostics Deals: Therapeutic Area Trends" 。
此報告書除了說明體外檢驗藥的概要與收購合併動向、各疾病種類的交易動向，也探討企業策略及未來體外檢驗藥交易的展望等。此報告書的概略架構如下所示。
摘要
說明
背景：體外檢驗藥市場
- 認知：小規模獲利且認知度低
- 體外檢驗藥市場：利潤大餅中的一塊
- 主要企業：增加市場投入製品數且提高市場佔有率
- 主要獲利：市場間及企業間的界線不明顯
體外檢驗藥的收購合併：大規模交易與新參與者
癌症的相關交易
心血管疾病的相關交易
感染病的相關交易
其他治療領域的相關交易
與企業策略的關係
體外檢驗藥交易的未來
表
- 體外檢驗藥市場區塊
- 體外檢驗藥的主要供應商
- 體外檢驗藥的相關收購與合併：2005∼2006年
- 癌症的體外檢驗藥交易：2005∼2006年
- 心血管疾病的體外檢驗藥交易：2004∼2006年
- 感染病的體外檢驗藥交易：2004∼2006年
- 其他治療領域的體外檢驗藥交易：2003∼2006年
Abstract
"Given the health care industry' s reliance on diagnostics to properly treat
patients, deals between diagnostics companies bode well for all facets of
industry. While larger companies are likely to continue to consolidate,
smaller companies and academic institutions will stay active in deals by
licensing biomarkers and technologies." - Catherine Cuddihee, M.S.,
Principal Director
Introduction
IVD (in vitro diagnostics) tests are essential to the practice of health care
worldwide: an estimated 60-70% of medical decisions involve a diagnostic test.
This report focuses on IVD industry deals of the last few years and what they
reveal about the current strategies of some of the industry' s larger and
smaller companies.
Get the Answers You Need to Shape Your Strategy
Currently, IVD company revenues pale in comparison to those of the larger
biopharmaceutical companies, but there are signs of steady growth in this
highly segmented market. What is the value of today' s global IVD market?
How fast is it growing? Which segments are currently most profi table? Which
are showing strong growth? Which IVD suppliers accounted for nearly 80% of
worldwide sales in 2005?
Several large IVD M&As have occurred in recent years, but licensing deals have
been the most common type. How do licensing deals benefi t IVD suppliers?
What do big pharmaceutical and diagnostics companies gain? Which companies
have been most active in M&A and licensing deals? What does this activity
indicate about the future of the IVD industry?
The overall oncology therapeutic area has accounted for the majority of IVD
deals to date. Which oncology segments are most active? What other
therapeutic areas are generating notable deals? What types of diagnostic
assays and tests are most in demand? Which are being offered as "companion
diagnostics" to therapeutic agents? What new, DNA-based tests are in
development?
Scope
- The IVD marketplace: Current size, growth, segmentation, disease
areas, major and smaller IVD suppliers, 2005 sales.
- IVD mergers and acquisitions: 2005-2006, companies, segments,
values, signifi cance.
- IVD deals by disease areas: Oncology, cardiovascular, infectious
diseases, other therapeutic areas.
- IVD deal strategies: Different strategies drive deals in different
tiers of the IVD industry.
- Future IVD deals: Potential mergers and acquisitions as diagnostics
change and the IVD market continues to grow.
Mentioned in This Spectrum Report-Companies
- Abbott
- Affymetrix
- Agendia
- American Diagnostica
- Applied Imaging
- Arcturus
- AstraZeneca
- Athena Diagnostics
- Bayer Diagnostics
- Becton Dickinson
- Beckman Coulter
- BioMerieux
- Biosite
- CanAg Diagnostics
- Ciphergen
- Clarient
- Clinical Data
- Competitive Technologies
- Cytyc
- Dade Behring
- Diagnostic Products
- Corporation
- Diagnostic Systems
- Laboratories
- Epigenomics
- Exact Science
- Fisher Scientifi c
- Fujirebio Diagnostics
- GE Healthcare
- GeneOhm Sciences
- Gen-Probe
- Genzyme
- Health Discovery
- Corporation
- Inverness Medical
- Innovations
- Johnson & Johnson
- LabCorp
- LifeScan
- Lumigen
- Merck
- Monogram Biosciences
- Oncogene Sciences
- Oncomethylome Sciences
- Orion Genomics
- Ortho-Clinical
- Diagnostics
- Pathwork Informatics
- Power3 Medical
- Primagen
- Quest Diagnostics
- Ranbaxy Laboratories
- Response Biomedical
- Roche
- Rubicon Genomics
- Siemens
- Thermo Electron
- TriPath
- Veridex
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Background- The IVD Marketplace
- Perceived Value: Smaller Revenues Command Little Respect
- The IVD Market- Pieces of the Pie
- The Major Players- More Offerings Increase Market Share
- A Bigger Pie- Boundaries Between Markets and Players Are Blurring
- IVD Mergers and Acquisitions- Major Deals and a New Entrant
- Sidebar: Drivers of a Diagnostics/Discovery Market
- Oncology Deals
- Cardiovascular Deals
- Infectious Disease Deals
- Deals in Other Therapeutic Areas
- What Do Deals Tell Us About Company Strategies?
- What Does the Future Hold for IVD Deals?
Tables
- 1. In Vitro Diagnostics Market Segments
- 2. The Major Suppliers of In Vitro Diagnostics
- 3. Select In Vitro Diagnostics Mergers and Acquisitions, 2005-2006
- 4. In Vitro Diagnostics Oncology Deals, 2005-2006
- 5. In Vitro Diagnostics Cardiovascular Deals, 2004-2006
- 6. In Vitro Diagnostics Infectious Disease Deals, 2004-2006
- 7. Select In Vitro Diagnostics Deals in Other Therapeutic Areas, 2003-2006
|
